Search
forResearch 10 of 1000+
- Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus
- Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures
- Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI
- LO-009 Responsiveness of the CLASI to alopecia and mucous membrane involvement: a retrospective study of prospectively collected data
- All Subcomponents of the Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) are Relevant to Identify and Detect Changes in Skin Activity
- Comparative Analysis of Labeling and Claim Substantiation Requirements for Herbal Hair Products across Different Regulatory Jurisdictions
- Claims for the cost of care: local authority provision
- Extraordinary claims without extraordinary evidence: controversy on anti‐androgen therapy for COVID‐19
- Wellness claims and men’s health: Bridging the counseling gap in urology
- Validation of alopecia coding in US claims data among women of childbearing age
Learn 1 of 18
All learn results →Community 10 of 344
- Clascoterone Phase 3 Results and Efficacy
- Why isn’t Clascoterone being discussed more?
- Winlevi Clascoterone- resultssss
- Whatever happened to Clascoterone? (breezula for hair) (sold as Winlevi for acne available since 2021)
- Clascoterone full results 2026
- Why is everyone still arguing about PP405 when clascoterone is already heading toward regulatory submission?
- Clascoterone might be the Finasteride for female pattern hair loss.
- Clascoterone won't be available until q4 2027 at the earliest per the newest Cosmo Pharma newsletter
- How to mix raw Clascoterone (CB-03-01)?
- Clascoterone Scalp 2 Results in July?